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Autoimmune diseases are characterized by the dysregulation of the immune system which finally results in the break of tolerance to self-antigen. Even though the accurate etiology and pathogenesis of the majority of these diseases are still not clear, complex elements, including genetic, environmental, and hormonal factors, may provoke the autoimmune processes leading to the development of the disease. Concerning the role of derailed immune responses in the pathogenesis, aberrant processes both in the innate and adaptive immune system have been shown to participate in the disease initiation and perpetuation [1] . Within these processes, numerous studies have been demonstrated that Toll-like receptors (TLRs) have an essential role in various autoimmune diseases, including Sjögren's syndrome (SS), systemic lupus erythematosus (SLE), multiple sclerosis (MS), rheumatoid arthritis (RA), systemic sclerosis (SSc), and psoriasis [2, 3] .
Toll-Like Receptors
The innate immune system is the first line of host defense mechanisms against invading microorganisms and forms the basis of the development of adaptive immunity. Host cells expressing diverse pattern recognition receptors (PRRs) include TLRs, C-type lectin-like receptors (CLRs), retinoic acid-inducible gene (RIG)-I-like-receptors (RLRs), and nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs). These can recognize a wide range of pathogen-associated molecular patterns (PAMPs). These mechanisms trigger the intracellular signaling pathways, which results in releasing of proinflammatory cytokines, chemokines, and interferons (IFNs), as well as lead to the expression of co-stimulatory molecules [4] .
TLRs are the most characterized PRRs, which are capable of potently activating different cell types, which could be highly expressed on most immune cells, as well as other cell types, including chondrocytes, endothelial cells, and fibroblasts [5] . Their downstream signaling pathways lead to the production of a wide range of immune stimulatory cytokines and chemokines [6] . Aberrant activation of TLRs may result in unrestricted inflammatory responses; therefore, the family of TLRs may play a pivotal role in the development of autoimmune diseases.
Ten TLR subtypes have been identified in humans during the last decade. All of them have their specific ligands, expression profiles, and cellular localization. TLRs belong to the type I transmembrane proteins, which are composed of a transmembrane domain, an amino-terminal ectodomain responsible for PAMPs recognition, and a cytoplasmic carboxy-terminal Toll interleukin-1 receptor (IL-1R) homology (TIR) domain [7, 8] .
Among those, TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10 are generally regarded as extracellular receptors. Since TLR2 addressed as heterodimer in combination with TLR1 or TLR6, while TLR10 was indicated as originating from the TLR1/TLR6 precursor, they all function as heterodimeric receptors and recognize components of microbial cell walls and membranes including peptidoglycans and lipopeptides. TLR4 can recognize lipopolysaccharides (LPSs), specific for gram-negative bacteria. On the other hand, TLR5 also resides in plasma membranes and engage flagellin, a specific component for flagellated bacteria [9] [10] [11] .
The family of TLR3, TLR7, TLR8, and TLR9 are intracellular receptors located in endosomal compartments and responsible for the recognition of nucleic acids derived from viruses, bacteria, and the host. Double-stranded RNA (dsRNA) activates TLR3, while TLR7 and TLR8 recognize single-stranded RNA (ssRNA). More specifically, TLR9 recognizes unmethylated CpG DNA [9] [10] [11] .
As mentioned before, the TLRs differ in their expression pattern within various cell types. Their signal transduction pathways also have different mechanisms [12] . Two main adaptor pathways observed in TLRs signaling transduction, namely the myeloid differentiation primary response 88 (MyD88) and TIR-domain-containing adaptor inducing interferon (IFN)-β (TRIF, also known as TICAM1) pathway. MyD88 as an adaptor protein could bind directly to the cytosolic domain and lead to induction of gene expression via the transcription factors nuclear factor kappa-light-chainenhancer of activated B cells (NF-κB), activating protein (AP)-1, or interferon response factor (IRF)-1, IRF-5, and IRF-7. On the other hand, TRIF basically transmits the signal downstream and leads to activation of IRF-3 mainly together with NF-κB [13] [14] [15] [16] [17] .
TLR3 is the only TLR that exclusively uses the TRIFdependent pathways, whereas the other TLRs are restricted to the MyD88-dependent pathway. Exceptionally, TLR4 activates both pathways by first leads to activation of the MyD88 pathway at the plasma membrane then activates the TRIF pathway via TRIF-related adaptor molecule (TRAM) at the endosomes [11, 18, 19] . TLR4 was the first identified human TLR. TLR4 has been implicated in the recognition of viral structural and nonstructural proteins, which leads to the production of a wide range of immune stimulatory cytokines and chemokines [6, 20, 21] . Figure 1 summarizes the function and signalization of TLRs. Table 1 gives the brief summary of the TLR family.
IL-1-receptor-associated kinase (IRAK) family harbors the TIR domain of TLRs. It was originally regarded as the serine/ threonine kinase associated with the IL-1 receptor [22] . IRAK1, IRAK2, IRAK-M, and IRAK4 have been identified so far. Among those, IRAK1 and IRAK4 are two active kinases since they could harbor a critical aspartate residue, while this residue is not conserved in the other two members of IRAK, so-called inactive ones. IRAK proteins consist of a central kinase domain and an N-terminal ligand domain which mediates activation of MyD88. As the result of two kinase pathways, NF-κB together with mitogen-activated protein kinase (MAPK) pathways can be activated. Moreover, IRAK1 may play a role in tumor necrosis factor receptor (TNFR) superfamily-induced signaling pathways as well [23] .
MyD88 interacts with a cytoplasmic carboxy-terminal TIR domain of TLRs to recruit IRAK1 and IRAK4 upon stimulation. IRAK1 is further phosphorylated by the IRAK4 activation. Activated IRAK1 subsequently binds to the TNFreceptor-associated factor (TRAF) domain of TRAF6. The IRAK1/TRAF6 complex activates another complex which consists of the TGF-β-activated kinase 1(TAK1) and TAK1-binding proteins including TAB1, TAB2, and TAB3. Phosphorylation of the inhibitor of κB kinase (IKK) complex composed of IKK-α, IKK-β, and NEMO/IKK-γ and MAPK kinase 6 (MKK6) is induced by TAK1, and thereby induces the activation of NF-κB and MAPK [24, 25] .
Another proinflammatory cytokine, TNF-α, functions as a major mediator of apoptosis as well as immunity and inflammation, transduces its signals by binding with TNF receptors (TNFR-I and TNFR-II). The role of TNFR-II phosphorylation on its signaling properties is less understood than that of TNFR-I. TNFR-I takes most responsibility of TNF-α signaling when the death domain interacts with the death domaincontaining adaptor proteins such as TNFR-associated death domain (TRADD). Upon TRADD binding to the TNFR-I, it may lead to the recruitment of receptor-interacting protein (RIP) and TRAF2 in separate manner for NF-κB activation for the cell-protective pathway, while the recruitment of the complex of TRADD and Fas-associated death domain (FADD) results in programmed cell death [26] . On the other hand, TNFR-II does not contain this death domain in the cytoplasmic tail. The intracellular domain of TNFR-II contains a consensus motif that allows binding to TRAF2 directly [27] [28] [29] . The TRAF proteins are composed of four domains, which include the multiple zinc finger repeats (TRAF Zn-finger) that are involved in effector functions (essential for the activation of downstream signaling cascades), an amino-terminal really interesting new gene (RING)-finger, the N-terminal (TRAF-N) coiled-coil domains, and the C-terminal (TRAF-C) domains [30] .
In comparison with other TRAFs, TRAF6 has the most divergent TRAF-C domain and shows the least homology to the prototypical TRAF domain sequence [31] . There are distinct differences in peptide binding to TRAF6 and to the other TRAFs due to the special structure of TRAF6. Therefore, TRAF6 has its unique biological function. TRAF6 is a convergence point for both upstream and downstream signaling cascades. It regulates a variety of physiologic processes, including both innate and adaptive immunity, bone metabolism, cell proliferation together with differentiation and many others [32] . Unlike other TRAFs, which only mediate signaling from the TNFR superfamily, TRAF6 also participates in the signal transduction of IL-1R/TLRs to activate inflammatory and apoptotic signaling pathways [33, 34] .
Suppressor of cytokine signaling (SOCS) 1 was first identified and reported by three research groups with different methods in 1997. From then on, SOCS family set an important insight into the unelucidated mechanism of cytokine signaling. SOCS 1 is also known as Janus family kinase (JAK)-binding protein (JAB) or signal transducers and activators of transcription (STAT)-induced STAT inhibitor (SSI) 1 [35] [36] [37] . The SOCS family contains eight protein members, which are cytokine-inducible Src homology 2 (SH2) protein (CIS), SOCS1, SOCS2, SOCS3, SOCS4, SOCS5, SOCS6, and SOCS7. They all have a central SH2 domain, an aminoterminal domain of variable length and sequence, and the SOCS box which has a segment with a carboxy-terminal 40 amino acids. Activation of the intracellular molecules, including JAKs and STATs, is essential for the cytokine signaling [35] [36] [37] .
The SOCS family of proteins is regarded as key participants of the negative feedback loop that regulates the intensity, duration, and quality of immune cytokine signaling. Among the others, SOCS1 is one of the best characterized family members which is one of the multiple targets of miR-155. We have previously shown the expression pattern of miR-155 as well as the gene expression of SOCS1 in SS patients (unpublished data).
Cytokines such as IFN-γ, TNF-α, together with IL-4 upregulate the gene expression of CIS, SOCS1, SOCS2, and SOCS3 messenger RNA (mRNA). SOCS1 is also functioning as an inhibitor of the LPS-activated TLR signaling pathway through directly blocking IRAK1 and IRAK4 [7, 38] . MyD88-adaptor-like (Mal) is regarded as bridge for interacting with MyD88 of TLR2 and TLR4 signaling. SH2 domain of SOCS1 could recognize phosphorylated Mal and induce polyubiquitination and subsequent proteasomal degradation [39] . Targeted proteins and pathways of Toll-like receptors are summarized in Fig. 2 . Table 2 summarizes the structure of IRAK, TRAF, and SOCS family protein.
Primary Sjögren's Syndrome
Sjögren's syndrome (SS) is a slowly progressive systemic autoimmune inflammatory disease that primarily affects middle-aged women (female to male ratio 9:1), although it may be found in all ages including childhood. The target organs are salivary and lachrymal glands. Therefore, patients show symptoms of dry mouth and dry eyes [40] . Beside the pathognomonic glandular symptoms (GS), other systemic symptoms, denoted as extraglandular manifestations (EGMs), also found in approximately one third of the patients. These patients frequently complain about fatigue, Raynaud's phenomenon, and muscle and joint pains [41] .
The expression profile of various TLRs is quite different in primary SS patients compared to that of healthy individuals [42] . Cultured salivary gland epithelial cells (SGECs) have been shown to express functional TLR2, TLR3, and TLR4 following treatment with their respective ligands. The TLR1, TLR2, and TLR4 mRNAs are significantly overexpressed in primary SS SGECs compared to controls [42, 43] . The expression level of TLR2, TLR3, TLR4, and MyD88 is higher in the labial salivary glands of SS patients compared to controls. Therefore, it is informative to assess them in different salivary gland cell types, including acinar cells, infiltrating mononuclear cells, and ductal epithelial cells. The TLR expression level showed similar pattern in all types of human salivary gland cells [44] . As mentioned before, peptidoglycans could activate TLR2, which has been indicated to induce the production of interleukins such as IL-17 and IL-23 in the peripheral blood mononuclear cells (PBMCs) of SS patients via IL-6, STAT3 and NF-κB pathways [45] .
We reported previously the concurrent overexpression of miRNA-146 and TRAF6 gene in primary SS patients compared to controls [46] . The overexpression of TRAF6 is surprising since miR-146a could inhibit the expression of TRAF6 [47] . In the same patient pool, we could demonstrate a similar pattern with the concurrent enhanced expression of miRNA-155 and SOCS1. In both cases, the overexpression of TRAF6 and SOCS1 was related to the levels of miRNAs. These phenomena may be explained by the following possible reasons: (a) existence of chronic persisting EBV infections; (b) the function of TRAF6 and SOCS1 might be complemented by other TRAF and SOCS molecules and signaling factors, and (c) miR-146a and miR-146b are not the only miRNAs which target TRAF6 protein whereas miR-155 is also not the only miRNA which targets SOCS1 protein.
Previously, we have assessed circulating cytokines in primary SS patients compared to healthy controls and found among others that serum IL-10 level was significantly decreased in primary SS patients [48] . The impaired IL-10 signaling might be associated with SOCS1 induction. Overexpression of SOCS1 in primary SS could be correlated to these results.
Systemic Lupus Erythematosus
SLE is the most prevalent systemic autoimmune disease which has a large spectrum of clinical presentations since SLE can affect multiple organs, including skin, joints, kidneys, lungs, nervous system, and serous membranes. Its diversity of clinical features is matched by the complexity of the . Activated IL-1-receptor-associated kinase (IRAK) 4 could further phosphorylated IRAK1. Activated IRAK1 binds to TNF-receptor-associated factor (TRAF) 6 to form the IRAK1/TRAF6 complex, which activates TGF-β-activated kinase 1(TAK1) and their binding protein (TAB1, TAB2 and TAB3) complex. Subsequently activates inhibitor of κB kinase (IKK) complex (IKK-α, IKK-β, and NEMO/IKK-γ) and mitogen-activated protein kinase (MAPK) in different pathway, which leads to activating nuclear factor kappa-light-chainenhancer of activated B cells (NF-κB) and activating protein (AP)-1. Furthermore, IRAK1 also imply a role in tumor necrosis factor receptor (TNFR)-superfamily-induced signaling pathways. The TNFR separates into two groups based on whether the death domain presence or not. When TNFR-I interacts with the TNFR-associated death domain (TRADD), it may lead to the recruitment of receptor interacting protein (RIP) and TRAF2 for NF-κB activation. The recruitment with Fasassociated death domain (FADD) result in programmed apoptosis. Even though the TNFR-II does not contain the death domain, the intracellular consensus motif could bind to TRAF2 directly pathogenetic factors including genetic, hormonal, and environmental factors [49] .
Human plasmacytoid dendritic cells (pDCs) regarded as critical elements involved in the pathogenesis of autoimmune diseases [50] . They can produce cytokines and chemokines in response to autoimmune complexes including self DNA and small nuclear ribonucleoprotein particles (snRNPs) in SLE through a cooperative interaction between TLRs and Fc-γ receptors (Fc-γ-Rs) [51, 52] . Both TLR7 and TLR9 are associated with the stimulation of B cells and the production of IFN-α in SLE. TLR7 showed higher expression level on human pDCs compared with the other RNA-activated endosomal TLRs, TLR3 or TLR8 [51] . TLR7 binding with U1 snRNP mediated by Fc-γ-Rs results in a massive release of IFN-α [51] . TLR7 antagonists could inhibit IFN-α production by pDCs in response to nucleic acid-containing immune complexes [52, 53] . On the other hand, it is also believed that the production of type I IFN (i.e., IFN-α and IFN-β) and TNF-α in SLE is highly related with TLR9 [53] . The immune complexes derived from serum of SLE patient are translocated to the endosome for activating TLR7 or TLR9, resulting in dimerization and internalization leads to IFN-α or TNF-α secretion. Increased levels of IFN-α in serum and higher expression level of IFN-inducible genes in PBMCs extracted from SLE patients have been suggested to be responsible for severe stage of disease activity [54, 55] . Activation of TLR9 through transcription factor IRF7 which is activated by the adaptor MyD88 leads to high level of IFN induction. The MyD88/IRF7 complex together with A/D-type CpG oligodeoxynucleotide (CpG-A, an IFN-inducing TLR9 ligand) is normally retained in the endosome of pDCs. CpG-A is rapidly transferred to lysosome when in conventional dendritic cells induces the production of type I IFN [56] . During immune stimulation, uridine-rich RNAs are recognized by pDCs via TLR7, while human monocytes and myeloid DCs through TLR8 [51] . Myeloid DCs respond to TLR7/ 8 ligands via Fc-γ-Rs, which leads to the production of IL-12 and the induction of T helper type 1 (Th1) cell proliferation [57] .
Interferon, TNFs, and specific interleukins are induced by TLRs. For instance, the expression of TNF-α, IL-6, IL-23, and IL-10 is induced by TLR4 activation [58] . TLRs are activated in response to accumulation of apoptotic bodies. TLR7 and TLR9 expression levels were significantly increased in African American and European American lupus patients compared to age-matched controls. Serum levels showed significant increase in expression of IL-6, INF-α, IFN-γ, and TNF-α in lupus patients compared to healthy individuals [59] .
The TLR4 polymorphism has not been found to be associated with the susceptibility to SLE so far. The Mal protein, also known as the TIR domain-containing adaptor protein (TIRAP), is implied to have a role in modulating intracellular signaling triggered by the MyD88-dependent TLR2 and TLR4. The Leu180 allele of MAL/TIRAP polymorphism indicated reduced susceptibility to SLE regarded as a protective factor against the development of SLE [60] .
The single nucleotide polymorphisms (SNPs) of TLR7 rs3853839, TLR8 rs3764880, together with TLR9 rs351240 have been shown to increase the risk of SLE in an Asian population [61, 62] . Moreover, the SNPs of TLR9 rs352139 and rs351240 are associated with lupus nephritis [63] . In a Danish population, the SNPs of TLR3 rs3775291, TLR8 rs3764879, and TLR9 rs352143 all showed association with SLE. The mRNA expression levels of TLR7 and TLR8 are also significantly higher in SLE patients than those in healthy controls [64] . These results indicate that genetic variations of certain TLR gene expression are implicated in the pathogenesis of the disease, which together associate with SLE susceptibility and clinical phenotype development.
The polymorphisms (rs11465955, rs1624395, rs1152888, and rs1370128) of IRAK-M in 2033 SLE patients compared with 2357 healthy controls from four independent European- IRAK IL-1 receptor associated kinase, TRAF TNF-receptor-associated factor, SOCS suppressor of cytokine signaling, CIS cytokine-inducible Src homology 2 (SH2) protein descent populations (Spain, Germany, Italy, and Argentina) were checked previously. The SNP rs1152888 of IRAK-M was not associated with SLE in these populations, while the other three showed differences between patients and controls [65] .
However, the expression and pathophysiological role of TNF adapters in SLE have been poorly understood so far. Zhu et al. found that the expression of mRNA for TNF adapter molecules TRADD protein, FADD protein, RIP, and TRAF2 decreased significantly in PBMCs from patients with SLE. Moreover, the expressions of these adapters were negatively correlated with the SLE disease activity index (SLEDAI) [66] .
Being expressed in immune cells, suppressors of cytokine signaling proteins, CIS, SOCS1, SOCS2, and SOCS3, can regulate cytokine signaling and immune responses. To evaluate the possible expressional dysregulation of CIS, SOCS1, SOCS2, and SOCS3 in SLE and RA patients, the transcript levels of these genes in PBMCs from SLE and RA patients were determined and statistically compared with those in PBMCs from healthy individuals. SLE patients with active disease significantly express higher CIS transcript levels than normal individuals and SLE patients with inactive disease, whereas the difference in SOCS1, SOCS2, and SOCS3 transcript levels between normal individuals and SLE patients are not statistically significant. These data suggest that CIS can serve as an SLE disease marker and may be involved in the pathogenesis of SLE, and that TNF-α may play an important role in the regulation of CIS and SOCS2 gene expression in PBMCs in vivo [67] . In monocytes, higher expression level of STAT1 proteins was shown from SLE patients compared to controls, which also positively correlated with SLEDAI. The expressions of phospho-STAT1 protein and SOCS1 gene in the skin lesion from patients with SLE were both upregulated compared with normal skin tissue from healthy controls. In conclusion, the JAK-STAT1 signaling pathway was hyperactivated while SOCS1 was downregulated in skin lesions and monocytes of Asian SLE patients [68] .
Additionally, TLR2 and TLR4 could be necessary for the initiation of antiphospholipid antibody production and activation of the endothelium, resulting in thrombosis development in the pathogenesis of antiphospholipid syndrome secondary to SLE [69] .
Multiple Sclerosis
MS is an autoimmune neurological disease that affects the brain and the spinal cord and leads to main triad symptoms of inflammation, demyelination, and gliosis. MS is causing the nerve signals to slow down or even stop due to damaged or lack of the protective covering of myelin sheath surrounding the nerve cells, resulting in single or multiple symptoms including motor disabilities, speech disabilities, swallowing disabilities, visual disabilities, and other neuronal problems [70] .
The activation of the transcription factor NF-κB may be implied in the microglial response to myelin damage in MS lesions. Upregulation of NF-κB-controlled adhesion molecules and cytokines result in enhancement of the inflammatory reaction [71] . After stimulation with TLR ligands and cytokines that induce NF-κB, the expression of NF-κB DNAbinding activity was elevated in macrophages of MS patients [72] .
TLR ligands have also been identified as T cell promoter of MS [73] . TLRs have diverse roles in forming of axonal path, dorso-ventral patterning together with cell fate determination. Specifically, TLR2 and TLR4 differentially modulate adult hippocampal neurogenesis through unknown ligands [74] . TLR ligands can inhibit the differentiation of several cell types; TLR2 ligands can suppress the process that the mesenchymal stem cells differentiated into osteogenic, adipogenic, and chondrogenic cells [75] . The expression of TLR2 observed on oligodendrocytes, while higher expression of TLR2 in MS lesions. Hyaluronan receptor is capable of inhibiting the maturation and remyelination oligodendrocyte precursor cells (OPCs) via TLR2 [76] . TLR2 also associated with the high levels of hyaluronan found in the areas of complete demyelination in MS. Altered TLR2 activation results in the dysfunction of hyaluronan synthesis and degradation on oligodendrocytes, which may imply the adequate remyelination blockade [77] . TLR9 was identified in B cells and pDCs [78] . Human TLR9 is only found on pDCs and is able to recognize viral DNA within the early endosomes at the initial phase of viral infections since TLR9 recognizes unmethylated CpG DNA [79] . Both TLR2 and TLR9 has been associated with the response to several human viral infections, including cytomegalovirus, hepatitis C, EBV, varicella zoster virus, and herpes simplex viruses (HSV) types 1 and 2 [80] [81] [82] . Activation of TLR2 induces the production of proinflammatory cytokines, including IL-6, IL-8, and TNF-α. Moreover, TLR9 stimulated by HSV triggers the production of IFN-α [83] . Furthermore, TLR7 also play a role implied in MS. TLR7 triggers the maturation and differentiation status of B cells into immunoglobulin (Ig)-secreting plasma cells, which leads to the release of IgM and IgG. It is indicated that deficient TLR7 induced immunoglobulin production in MS recently. The MS aggravation could be associated with impaired immune responses against infections with TLR7-recognized RNA viruses [84, 85] .
The SNP rs243324 of SOCS1 variant regarded as risk factor for MS in a separate cohort of 3919 MS patients and 4003 controls in Spain population. Moreover, its T allele was increased in relapsing remitting (RR) MS which also named secondary progressive MS patients than primary progressive MS patients [86] .
SOCS proteins, especially SOCS1 and SOCS3, not only expressed in immune cells but also have been described in the cells of the central nervous system (CNS). Besides the immunomodulating functions in the immune system, SOCS family also activate microglia, macrophages, and astrocytes [87] . A moderated negative correlation has been depicted between SOCS1 and SOCS3. SOCS1 transcription level was lower in the peripheral blood leukocytes of MS patients compared with healthy controls, while SOCS3 was shown to have higher transcription level [88] . The presence of SOCS1 inhibits the process of IFN-γ induction of TNF-α secretion and STAT-1α and NF-κB activation, resulting in the reduction of CD40 both at protein and mRNA levels [89] .
The expression level of SOCS3 is lower in CD4 + and CD8 + T cells from RR MS patients during relapse compared with MS patients in remission [90] . Lower expression level of SOCS3 results in increasing the activation of STAT3, causing massive release of the hormone leptin in CSF of MS patients, and other MS lesions [91] . Leptin has the function of triggering TNF-α, IL-6, and IL-10 expression in monocytes of relapsing MS patients but not in monocytes of the patients with stable disease stage. Indeed, decreased SOCS3 expression level during relapses might account for overexpression of leptin-mediated cytokine in MS [92] . On the other hand, Th17 cells have been implied to have an essential role in pathomechanism of autoimmune diseases. Th17 cell lineage transcription factors, signal transducer, and activator of the transcription (i.e., STAT3) lead to the activation of the specific cytokines close associated with Th17, including IL-17A, IL-17F, IL-21, and IL-22. It is indicated that IL-1 receptor type 1 (IL-1R1) signaling is highly related with the differentiation and activation of Th17 cells. IL-1R1 signaling induces Th17 cell differentiation results in the expression of IRAK4 together with retinoic acid-related orphan nuclear hormone receptor (ROR). Therapeutic strategies with inhibiting IL-1R1 signaling can be regarded as a novel approach for the treatment of MS based on the role of IL-1 signaling and Th17 cells in the development of the autoimmune processes and autoimmune diseases. Negative regulators including inhibitory membranebound IL-RII, the regulatory IL-1R1 antagonist (IL-1R1a) and the IL-1R1-signlaing-induced single Ig IL-1R-related (SIGIRR) suppress excessive IL-1 signaling and Th17 cell differentiation [93] . IFN-β has been used as preferred therapy for MS by suppressing the differentiation of Th17 cells via inducing the production of Th17-suppressive cytokines including IL-27 and IL-12 in DCs. SOCS3, regarded as important regulator of leptin-mediated protein, inhibited the production of the Th17-promoting cytokines IL-6 and IL-23 [94] . Surprisingly, statins used for controlling cholesterol levels such as simvastatin also have anti-inflammatory and immunomodulatory effects. It induces SOCS3 expression in monocytes from RR MS patients, leading to the lower activation of STAT1 and STAT3, which blocks the development of Th17 cells. The production of Th17-promoting cytokines IL-6 and IL-23 is further inhibited as the result, leading to the decreased IL-17 production and inhibition of the expression of IL-17 transcription factor RORC in CD4 + T cells [95, 96] . Statins blocking the development of Th17 might be protective in MS; therefore, they are being tested in clinical trials in MS patients currently [97] .
Additionally, torque teno virus (TTV) is also involved in the pathogenesis of MS. TTV interact with TLRs, which leads to the production of inflammatory cytokines, contributing to the chronic disease progression in MS patients. Overexpression of TLR9 on monocytes of MS patients is correlated with higher titers of TTV in blood [98] .
Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a common autoimmune disorder with prevalence rates approximately 1 % of the adults worldwide. The disease primarily affects the synovial joints, and the chronic inflammatory process consequently causes the destruction of the articular tissue [99] .
Several genetic studies address the association of the common SNP of TLR and the pathogenesis of RA. The results somewhat vary from region to region. The TLR9 SNP rs187084 allele variant TT may increase RA susceptibility in the Turkish RA population, although it was not associated in studies of Dutch or French cohorts [100] [101] [102] . Furthermore, the SNP rs5741883 of TLR8 has been revealed to have association with rheumatoid factor autoantibody positivity in a cohort study on 319 European individuals [103] .
Besides the assessment of SNP of TLRs in RA patients, functional studies on TLRs in human RA samples identified increased activation status of these receptors. It is suggested that the adaptor protein used by most TLRs, MyD88, is essential in matrix metalloproteinase (MMP) production which is responsible for the tissue destruction and remodeling in RA synovial membrane cultures [104] . Therefore, TLRs have potential involvement in the inflammatory and destructive processes in RA. Furthermore, TLR3 can also promote osteoclastogenesis via upregulation of receptor activator of NF-κB ligand (RANKL, also known as osteoclast differentiation factor) on RA synovial fluids (SFs) causing chronic inflammation [105] . RA necrotic synovial fluid cells have been shown to release RNA regard as endogenous TLR3 ligand that can activate TLR3 on RASFs [106] .
TLR signaling pathways have correlated with the development and maintenance of RA. Many studies have investigated the expression and function of TLRs in synovial tissue cells from patients compared with tissue samples from osteoarthritis (OA) patients or healthy controls. All endosomal TLRs including TLR3, TLR7, TLR8, and TLR9 were expressed not only in peripheral blood but also in human synovial tissue of RA patients [106] [107] [108] . A variety of TLRs including TLR2, TLR3, TLR5, TLR6, TLR7, and TLR9 showed overexpression in the synovium of RA patients compared with healthy controls or OA patients [109] [110] [111] . TLR2 has essential pathogenic function in RA; activation of synovial fibroblasts via TLR2 induces the production of multiple inflammatory chemokines including IL-1β and TNF-α in RA joints [112, 113] . TLR2 and TLR4 expression was found associated with the presence of IL-12 and IL-18 in RA synovial tissue [111] . Activation of TLR-3 and TLR-7/8 resulted in a skewed balance toward IL-12 [114] . DCs derived from RA patients have shown elevated levels of inflammatory cytokines such as TNF-α and IL-6 mediated by activation of TLR2 and TLR4 compared with healthy controls [114] . Stimulation of synovial fibroblasts with the TLR3 ligand results in releasing IL-6, MMP-3, and MMP-13 [108] . It is observed that TLR8 induced the massive secretion of TNF from RA synovium. Using imiquimod (inhibition of spontaneous TNF production) specifically inhibits TLR8 [107] .
Further data on the contribution of these TLRs in the perpetuation of inflammation in RA comes from studies with antimalarial drugs, such as chloroquine, hydroxychloroquine, and quinacrine, which have been used to treat RA in the last century [115, 116] . These drugs act as antagonists of TLR9 and inhibit endosomal acidification [117] . They could also interact directly with nucleic acids, causing modifications which prevent their binding to the endosomal TLRs [118] .
SOCS protein levels can dramatically modulate cellular responses to cytokines through the JAK-STAT pathway. The overexpression of SOCS1 and SOCS3 were detected in PBMCs from RA patients compared with healthy controls and could relate with the upregulation of SOCS1 in T cells and SOCS3 in monocytes. SOCS1 also had higher expression in the synovial membranes from RA patients compared with OA patients. Moreover, SOCS2 was upregulated in T cells. Intriguingly, T cells in synovial fluid expressed lower levels of SOCS molecules than in the peripheral blood. Furthermore, macrophages in synovial fluid have higher levels of SOCS molecules than in the peripheral blood [119] . The transcript levels of CIS, SOCS1, SOCS2, and SOCS3 genes in RA patients compared with normal individuals were not reaching statistical significant level. However, the RA patients group using treatment with TNF-α blocking agent appeared to have overexpression level of CIS, but lower expression of SOCS2 in PBMCs [67] .
The expression of TNF-α and related signaling molecules were detected in PBMCs from 27 Indian RA samples and 30 controls. Significant overexpression of TNF-α and TNFR-I together with increased expression of TRADD, RIP, and TRAF2 mRNA indicated the enhanced signaling through TNFR-I-TRADD-RIP-TRAF2 pathway in RA patients compared with controls. Lower expression of FADD may suggest the suppressed signaling via TNFR-I-TRADD-FADD pathway [120] .
Even though the role of variations in the TNF-α gene remains not completely known for the pathomechanism of RA, the factors regulating TNF-α signaling may contribute to RA susceptibility. The TRAF family members are one of the most characterized molecules transducing cytokine signals from their cell surface receptors and activating downstream intracellular signaling cascades. The SNP rs7514863 of the TRAF5 gene identified a significant association across the entire cohort of 1273 cases with RA compared with 2463 healthy controls of UK Caucasian population [121] .
Lee et al. studied the TNF-α-driven inflammatory program in fibroblast-like synoviocytes (FLSs) obtained from the synovial tissues of patients with RA. They discovered the TNF-α-induced prolonged activation of NF-κB signaling and sustained transcriptional activity in FLSs of RA compared with OA. Moreover, lower expression of the feedback inhibitors A20-binding inhibitor of NF-κB activation 3 (ABIN3), IRAK-M, SOCS3 and activating transcription factor 3 (ATF3) was indicated in FLSs. Since those four factors may terminate inflammatory responses in macrophages, while in FLSs, they had lower expression, resulting in uncontrolled inflammatory response which leads to persistent synovial inflammation in RA [122] .
Systemic Sclerosis
Systemic sclerosis (SSc) is characterized by sclerosis in multiple systems including the skin, lungs, gastrointestinal tract, kidneys, and the musculoskeletal system. SSc is classified into two subgroups based on the extent of skin thickening: limited SSc and diffuse SSc. The limited form is at lower risk of visceral involvement, while the diffuse form involves several systems of internal organs [123] .
It is believed that many TLRs participate in the development of the dysfunction of the immune system in SSc. For instance, TLR agonist S100A8/A9 regarded as a novel possible marker for SSc phenotype [124] . A SNP of TLR2 (Pro631His) variant was suggested to be associated with the diffuse form of SSc and the development of pulmonary arterial hypertension (PAH) [125] .
On the other hand, Siglec-1 (CD169, sialoadhesin) is a IFN-regulated gene that was regarded as macrophage marker. Certain TLR agonists, including TLR-7 and TLR-9, trigger the induction of Siglec-1 mRNA and surface protein expression in circulating monocytes and tissue macrophages of SSc patients compared with healthy controls. By immunohistochemistry, they observed higher amounts of Siglec-1+ cells in the skin of SSc patients compared with controls. Certain upregulated TLRs through the IFN-mediated gene imply their essential role in the pathomechanism of SSc [126] .
The T cell attracting and profibrotic chemokine CCL18 showed higher levels in SSc. The monocyte-derived DCs matured with the TLR4 ligand LPS from SSc patients release significantly increased levels of IL-10 compared with healthy controls, which suggest a role for TLR4 ligands in the pathogenesis of SSc [127] .
Other profibrotic and proangiogenic chemokines such as CCL2 and CXCL8 have also shown relation with SSc. CCL2 production was sensitive to both inhibition of proteasome and JNK, while CXCL8 production was sensitive only to inhibition of proteasome. Excessive production of these two chemokines in antifibroblast antibodies (AFAs)-stimulated fibroblast culture supernatants resulted in activation of ERK-1/ 2, c-Jun, and NF-κB. Furthermore, anti-human TLR4 monoclonal antibodies (mAb) partially inhibited the production of CCL2 induced by AFAs in human fibroblasts; in other words, CCL2 induction is TLR4 dependent [128] .
Autoantibodies that bind to the surface of fibroblasts may contribute to the pathogenesis of SSc. Furthermore, EBV activates TLR pathway in infected SSc fibroblasts. In EBV/ p2089-infected SSc fibroblasts (in vitro), a significant induction of mRNA expression levels of TLR7 and TLR9, selected IFN-stimulated genes (ISGs), IRF7, IRF5, and IRF4 have been described [129] .
MMPs are capable of degrading all extracellular matrix (ECM) components [130] . Tissue inhibitors of metalloproteinase (TIMPs) are induced by MyD88-dependent TLRs, especially TLR8, selectively inhibits MMPs to block the breakdown of ECM [130, 131] . TIMP-1 is the most characterized enzyme among the TIMP family since it can inhibit most MMPs [130] . Therefore, higher serum concentrations of TIMP-1 result in the increment in the ratio of TIMP/MMP of patients with SSc [132] [133] [134] [135] . Increased TIMP-1 production has been described in circulating monocytes of SSc compared with RA patients and controls. When SSc and control monocytes were stimulated with TLR8 agonist, TIMP-1 production dramatically elevated, underlining the role of TLR signaling in ECM remodeling [136] .
Psoriasis
Psoriasis is a chronic and frequently relapsing inflammatory skin disease characterized by pathologic features such as accelerated epidermopoiesis, marked hyperkeratosis with parakeratosis (abnormal maturation), vascular dilatation, and inflammatory cell infiltration. The most common form of the disorder is the chronic plaque psoriasis with rounded erythematous, dry, scaling patches. The lesions have a predilection site as nails, scalp, genitalia, extensor surfaces, and the Elevated levels of TNF-α and IL-6 derived from DCs lumbosacral region. The etiology of the disease is not fully understood, but genetic factors are highly believed to be involved [137] . TLR1, TLR2, and TLR5 have been detected to be constitutively expressed on the normal keratinocytes in the epidermis. Interestingly, the expression of TLR1 and TLR2 on keratinocytes in the psoriasis skin lesions is further upregulated [138] . The higher expression of TLR4 in guttate psoriasis was indicated compared with plaque psoriasis and normal controls [139] . The enhanced TLR2 expression could further upregulate TLR4 expression in epidermal and dermal DCs of psoriatic skin [140] . Psoriatic keratinocytes induce high levels of inflammatory mediators and become hyperproliferative upon IFN-γ and TNF-α stimuli, resulting in thickening of the skin. The TLR-7/8 agonist imiquimod stimulated IFN-γ and enhanced DCs infiltration, resulting in psoriatic exacerbations [141] . Among the other TLRs, TLR5 and TLR9 were upregulated by transforming growth factor-α (TGF-α) in psoriatic epidermal keratinocytes [142] .
The common coding variants of TRAF3IP2 gene p.Asp10Asn allele (rs33980500) regarded as risk factor for psoriatic arthritis. Downregulated TRAF3IP2 variant disrupted the binding property to TRAF6, indicating altered Suppress cytokine-induced apoptosis by blocking the proteasome [148] Higher expression in the IFN-γ and TNFα-activated psoriatic keratinocytes SOCS1 Mimetic peptide to control IFN-γ-mediated skin disorders [149] TLR2/3/4 Induce production of TNF-α and IL-8 [150] IL interleukin, PBMCs peripheral blood mononuclear cells, Th T helper, SGECs salivary gland epithelial cells, IFN interferon, pDCs plasmacytoid dendritic cells, TNF tumor necrosis factor, STAT signal transducers and activators of transcription, OPC oligodendrocyte precursor cells, HSV herpes simplex virus, TTV torque teno virus, RANKL receptor activator of nuclear factor κB ligand, OA osteoarthritis, MMP matrix metalloproteinase, FLSs fibroblast-like synoviocytes, ECM extracellular matrix, Ig immunoglobulin modulation of immunoregulatory signaling such as IL-17 in a German population [143, 144] . IFN-α and skin infiltrating activated T lymphocytes are also involved in the pathogenesi s of psoriasis. Downregulation of the SOCS3 together with SH2-domaincontaining protein-tyrosine phosphatase 1(SHP1) in response to IFN-α was found in the psoriatic T cells compared to that of healthy controls [145] . Intriguingly, SOCS1, SOCS2, and SOCS3 proteins were barely undetectable and only weakly expressed in atopic dermatitis skin [146] . MiR-203 is the keratinocyte-derived microRNA with a highly skin-specific expression profile. Its upregulation in psoriatic plaques was concurrent with downregulation of SOCS3, which is a miR-203 conserved target [147] .
Conversely, Federici et al. found exaggerated expression of SOCS1 and SOCS3 in the psoriatic epidermis and allergic contact dermatitis in the IFN-γ and TNFα-activated psoriatic keratinocytes. By sustaining the activation of the PI3K/AKT pathway in keratinocytes, SOCS1 and SOCS3 could suppress cytokine-induced apoptosis by blocking the proteasome [148] . SOCS1 mimetic peptide to control IFN-γ-mediated skin disorders is regarded as a new future perspective in psoriasis therapy [149] .
The expression of TNF-α and IL-8 induced by the TLR2, TLR3 and TLR4 signaling pathways via NF-κB nuclear translocation in human psoriatic keratinocytes have been described previously [150] . Some immunosuppressive therapies, such as pimecrolimus and tacrolimus, work in the way that suppress TLR2 signaling, which leads to downregulated of TNF-α and IL-8 mRNA expression in human keratinocytes to control psoriatic inflammation [151] . Topical retinoids also works as TLR2 inhibitors [152] , while monomethylfumarate interferes with LPS signaling that inhibits NF-κB via TLR 4 in dendritic cells results in lower expression of IL-12p70 and IL-10 [153] . Table 3 summarizes the association between SNPs and autoimmune diseases, while Table 4 summarizes the association between TLRs and autoimmune diseases.
Future Prospects
Activation of TLRs plays an important role in cytokine production in autoimmune diseases. IRAK, TRAF, and SOCS proteins are regarded as the main modulators of the TLR pathways. Addressing their gene expression profile together with SNP elucidation could be important to explain this aspect of the pathomechanism driving autoimmune diseases. Moreover, more targeted therapeutic potential could be utilized with more background knowledge on the TLRs family, such as statins use for the treatment in MS. Further studies on the identification of new families of other innate receptors (CLRs, NLRs, and RLRs) and their signaling pathways will help to understand individual TLR responses in innate immunity and aid more precisely in pinpointing therapeutic targets in patients with autoimmune diseases.
